ArticleJournal of virology1996
RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo.
Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Aptamers for Anti-Viral Therapeutics and Diagnostics.International journal of molecular sciences · 2021Review
- Review
- Aptamers in HIV research diagnosis and therapy.RNA biology · 2018Review
- RNA interference approaches for treatment of HIV-1 infection.Genome medicine · 2015Article
- Aptamers: multifunctional molecules for biomedical research.Journal of molecular medicine (Berlin, Germany) · 2013Review
- Novel cell and gene therapies for HIV.Cold Spring Harbor perspectives in medicine · 2012Review
- Single-nucleotide changes in the HIV Rev-response element mediate resistance to compounds that inhibit Rev function.Journal of virology · 2011Article
- Identification of antisense RNA stem-loops that inhibit RNA-protein interactions using a bacterial reporter system.Nucleic acids research · 2010Article
- Protective effects of anti-ricin A-chain RNA aptamer against ricin toxicity.World journal of gastroenterology · 2008Article
- Genetic therapies against HIV.Nature biotechnology · 2007Review
- Is gene therapy a good therapeutic approach for HIV-positive patients?Genetic vaccines and therapy · 2007Article
- Co-expression of anti-NFkappaB RNA aptamers and siRNAs leads to maximal suppression of NFkappaB activity in mammalian cells.Nucleic acids research · 2006Article
- Nucleic acid aptamers for target validation and therapeutic applications.Journal of biomolecular techniques : JBT · 2005Article
- Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.Nucleic acids research · 2002Article
- Gene therapy for HIV.Sexually transmitted infections · 2001Review
- A simple and efficient method to reduce nontemplated nucleotide addition at the 3 terminus of RNAs transcribed by T7 RNA polymerase.RNA (New York, N.Y.) · 1999Article
- Anti-Rex aptamers as mimics of the Rex-binding element.Journal of virology · 1999Article
- Polyvalent Rev decoys act as artificial Rev-responsive elements.Journal of virology · 1999Article
- Cytoplasmic RNA modulators of an inside-out signal-transduction cascade.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- A novel glutamine-RNA interaction identified by screening libraries in mammalian cells.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
RNA aptamers (binding sequences) that can interact tightly and specifically with the human immunodeficiency virus type 1 Rev protein have previously been selected from random sequence pools. Although the selected sequences compete with the wild-type Rev-binding element (RBE) in vitro, it was not known whether they would be able to functionally replace the RBE in vivo. Two aptamers that were different from the wild-type RBE in terms of both primary sequence and secondary structure were inserted into the full-length Rev-responsive element (RRE) in place of the RBE. The hybrid RREs were assayed for their ability to mediate Rev function in vivo using a reporter system. The aptamers were found to be functionally equivalent to the wild-type element when the assay system was saturated with Rev and better than the wild-type element when Rev was limiting. These results demonstrate that the affinity of the primary Rev-binding element rather than its particular sequence may be most responsible for conferring Rev responsiveness on viral mRNAs. Moreover, the fact that increased binding ability can lead to increased Rev responsiveness suggests that cellular factors do not directly influence the Rev:RBE interaction. Finally, since sequences distinct from the RBE are found to be Rev responsive, it may be possible for the RBE to readily mutate in response to drugs or gene therapy reagents that target the Rev:RBE interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.